Zelira Therapeutics (ASX:ZLD) EBITDA Margin %: 0.00% (As of Jun. 2025)


What is Zelira Therapeutics EBITDA Margin %?

Zelira Therapeutics ASX:ZLD EBITDA Margin % is 0.00% as of Jun. 2025. The stock has 7 warning signs investors should review. Among 944 Biotechnology companies, Zelira Therapeutics ranks worse than 99.05% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zelira Therapeutics's EBITDA for the six months ended in Jun. 2025 was A$-1.69 Mil. Zelira Therapeutics's Revenue for the six months ended in Jun. 2025 was A$0.00 Mil. Therefore, Zelira Therapeutics's EBITDA margin for the quarter that ended in Jun. 2025 was 0.00%.

Zelira Therapeutics  (ASX:ZLD) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Zelira Therapeutics EBITDA Margin % Related Terms

Zelira Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics EBITDA Margin % Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,854.97 -763.85 -1,876.08 -37,390.53 -317,200.00

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,021.88 -61,518.18 -4,215.00 -148,400.00 0.00

ASX:ZLD vs ENSC, PPCB, ACUT: EBITDA Margin % Comparison

For the Biotechnology subindustry, Zelira Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's EBITDA Margin % falls into.


Zelira Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Zelira Therapeutics's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-3.172/0.001
=-317,200.00 %

Zelira Therapeutics's EBITDA Margin % for the quarter that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-1.688/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Zelira Therapeutics (ASX:ZLD) has a EBITDA Margin % of 0.00% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zelira Therapeutics and its competitors. According to the industry distribution chart, Zelira Therapeutics ranks #935 out of 944 companies in the Biotechnology industry, placing it in the top 99%.
Is Zelira Therapeutics' EBITDA Margin % too high?
Zelira Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Zelira Therapeutics ranks #935 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Zelira Therapeutics' EBITDA Margin % compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Zelira Therapeutics ranks #935 out of 944 companies for EBITDA Margin %. This places Zelira Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current EBITDA Margin % of 0.00%. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current EBITDA Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.